BioAge Labs, Inc.

NASDAQ:BIOA

Biotechnology

Healthcare
$4.77 +2.35%

+$0.47 today

Market cap
$179.59M
Beta
0.95
P/E (TTM)
-9.7
EPS (TTM)
-$2.12
52W Low $4.07High $24.00

Volume 0.64M

Average 0.46M

BIOA Income Before Tax

Profit after all operating and non-operating items but before income tax.

BioAge Labs, Inc.NASDAQ: BIOA

Income Before Tax · Q1 FY2026 · quarter ended Mar 2026

Income before tax remains negative

Q1 FY2026 income before tax was -$22.25M, compared with -$12.93M a year earlier. Trailing-twelve-month income before tax was -$89.93M.

Context

  • Income before tax amounted to 896.1% of revenue in FY2025.
  • Income before tax grew in size in 3 of the last 3 fiscal years.
  • FY2025 was the largest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly income before tax holds near -$22.25M or moves back toward the trailing-twelve-month quarterly average of -$22.48M.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
-$22.25M+14.2% QoQ
Last fiscal yearDec 2025
-$80.61M-13.4% YoY
LTMMar 2026
-$89.93M-26.6% YoY
Income Before Tax past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-72.1%——
1 year-13.4%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Before Tax history

USD · from the income statement

Latest · FY2025
(80.61M) USD
Year-over-year change
-13.4%

Income Before Tax vs competitors

How BIOA compares with its peers on the latest reported figures

  • Peers report in different currencies, so income before tax is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -26.6% is the 6th highest of 9, against a peer median of +0.5%.
  • Income before tax amounts to 871.8% of revenue for BIOA, versus a peer median of 66.2%.
BIOA Competitors
Income Before Tax for BIOA and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ACBAurora Cannabis Inc.LTM Mar 2026-CA$5.04M CAD-124.7%—1.6%
TKNOAlpha Teknova, Inc.LTM Mar 2026-$17.09M USD+26.7%—40.9%
LFCRLifecore Biomedical, Inc.LTM Mar 2026-$33.68M USD——24.9%
BIOABioAge Labs, Inc.LTM Mar 2026-$89.93M USD-26.6%—871.8%
HUMAHumacyte, Inc.LTM Mar 2026-$97.59M USD-25.7%—4840.8%
EDITEditas Medicine, Inc.LTM Mar 2026-$108.95M USD+56.6%—281.6%
ALLOAllogene Therapeutics, Inc.LTM Mar 2026-$173.76M USD+31.0%——
CABACabaletta Bio, Inc.LTM Mar 2026-$175.43M USD-38.4%——
AVIRAtea Pharmaceuticals, Inc.LTM Mar 2026-$175.83M USD-26.9%——
CGCCanopy Growth CorporationLTM Mar 2026-CA$286.05M CAD+52.1%—91.6%
Peer median (excluding BIOA) —+0.5%—66.2%

Competitors are the stored peer set for BIOA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue0009M
Cost of Revenue0000
Gross Profit0009M
Gross Margin———100.0%
Research & Development30.52M33.89M59.04M73.97M
Selling, General & Admin9.45M14.51M19.16M27.81M
Operating Expenses39.97M48.4M78.19M101.78M
Depreciation & Amortization129K162K167K213K
EBITDA(39.35M)(55.9M)(68.58M)(79.7M)
EBITDA Margin———-886.0%
Operating Income(39.97M)(48.4M)(78.19M)(92.78M)
Operating Margin———-1031.5%
Interest Income465K2.43M9.63M13.09M
Interest Expense241K7.79M2.37M697K
Other Income / Expenses247K(15.45M)7.09M12.18M
Income Before Tax(39.72M)(63.85M)(71.11M)(80.61M)
Pre-Tax Margin———-896.1%
Income Tax Expense0000
Net Income(39.72M)(63.85M)(71.11M)(80.61M)
Net Margin———-896.1%
EPS (Basic)(1.16)(1.87)(1.98)(2.24)
EPS (Diluted)(1.16)(1.87)(1.98)(2.24)
Weighted Avg Shares34.17M34.2M35.85M35.93M
Weighted Avg Shares (Diluted)34.17M34.2M35.85M35.93M

BioAge Labs, Inc.

NASDAQ:BIOA

Intrinsic Alpha fair value

Locked

Current Price

$4.77

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.